Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

149.53 +0.73 (+0.49%)
Streaming Delayed Price Updated: 12:29 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Moderna Inc

< Previous 1 2 3 4 5 6 7 8 9
...
82 83 Next >
J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out
The company says it's refocusing its portfolio to focus on transformational medicines. 
Via Investor's Business Daily
Moderna's CEO Just Gave Investors a Huge Reason to Sell the Stock
The stock looks overpriced, and that's without taking into account all the risks. 
Via The Motley Fool
The Ultimate Growth Stock to Buy With $150 Right Now
Moderna's shares have climbed nearly 700% over the past five years. 
Via The Motley Fool
Check Out What Whales Are Doing With MRNA
 
Via Benzinga
2 Nasdaq 100 Stocks to Buy Hand Over Fist Right Now
Both have plenty of growth in the future, not to mention impressive histories. 
Via The Motley Fool
Looking At Moderna's Recent Unusual Options Activity
 
Via Benzinga
Could CRISPR Therapeutics Become the Next Moderna?
Both companies use cutting-edge technology. 
Via The Motley Fool
3 Things About Moderna That Smart Investors Know
Moderna stock has climbed more than 400% over the past three years. 
Via The Motley Fool
(MRNA) - Analyzing Moderna's Short Interest
 
Via Benzinga
Moderna, Generation Bio Collaborate To Develop Non-Viral Genetic Medicines
 
Via Benzinga
Why Generation Bio Shares Are Trading Higher Today
Generation Bio (NASDAQ: GBIO) shares are trading higher on Thursday after the company and Moderna (NASDAQ: MRNA) announced a collaboration to develop non-viral genetic medicines. 
Via Benzinga
7 Blue-Chip Stocks Sitting in the Sweet Spot
Although blue-chip stocks carry a reputation for being bulky and not exciting, these large enterprises can really move. 
Via InvestorPlace
Apple Jumps Movie Production Bandwagon, Billionaire Jim Ratcliffe Bids For Manchester United, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund: Today's Top Stories
Bloomberg 
Via Benzinga
Check Out What Whales Are Doing With MRNA
 
Via Benzinga
China's First mRNA Vaccine: Drugmaker CSPC Wins China's Approval For COVID-19 Vaccine
Chinese health authorities approved CSPC Pharmaceuticals Group Ltd's (OTC: CSPCY) messenger RNA (mRNA) COVID-19 vaccine for emergency use authorization. 
Via Benzinga
This Is What Whales Are Betting On Moderna
 
Via Benzinga
Additional COVID-19 Booster Shots? Officials Anticipate FDA Authorization Within Few Weeks
The U.S. Food and Drug Administration is reportedly moving toward authorizing a second round of omicron-targeted COVID-19 booster shots for the elderly and other people at high risk. 
Via Benzinga
If You Invested $5,000 in Moderna in 2020, This Is How Much You Would Have Today
Moderna might become a multiproduct company over the next few years. 
Via The Motley Fool
Covid Vaccine Battle Brewing: Moderna's Stephane Bancel Vs. Bernie Sanders
Moderna CEO Stephane Bancel will face a Senate Committee over pricing plans. 
Via Investor's Business Daily
Moderna Wants $130 Per COVID-19 Vaccine Dose, US Health Authorities Warn Of Incurable Deadly Fungal Infection, Elon Musk Wants Interest Rate Cut: Today's Top Stories
Reuters Moderna Wants To Charge About $130 Per COVID-19 Vaccine Dose 
Via Benzinga
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
 
Via Benzinga
Moderna Wants To Charge About $130 Per COVID-19 Vaccine Dose
From now on, Moderna Inc (NASDAQ: MRNA) expects to charge $130 per dose for its COVID-19 vaccine as purchases move from the government to the private sector. 
Via Benzinga
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories
Reuters 
Via Benzinga
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats 
Via News Direct
Topics Death Economy
Exposures COVID-19 Death Economy
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
With the COVID pandemic still ongoing, having claimed  more than 6.8 million lives from about 758 million cases and crippling the global economy, there are several reasons why drug research and... 
Via Benzinga
2 Undervalued Stocks to Buy Today to Prepare for the Next Bull Market
Both have some headwinds coming up, but their long-term outlook still looks great. 
Via The Motley Fool
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
 
Via Benzinga
12-Stock Portfolio -- 25 Growth Stocks to Buy Now
If I were starting a new growth stock portfolio today, here are the stocks I'd buy. 
Via The Motley Fool
Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?
An approved RSV vaccine could be the next big thing for these companies. 
Via The Motley Fool
Is It Time to Buy the S&P 500's 2 Worst-Performing February Stocks?
Lumen Technologies and Moderna just tumbled, but are these buying opportunities or falling knives? 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
82 83 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.